title: [Expression and significance of CD44 and angiogenic growth factor in nasal NK/T cells lymphoma].
abstract: OBJECTIVE
  To investigate the molecular basis of the high aggressiveness of nasal NK/T cells lymphoma.
  
  
  METHODS
  Immunohistochemical study was used on 17 cases of nasal NK/T cells lymphoma to examine CD20, CD43/CD45RO, CD3, CD56, TIA-1, and CD44. In situ hybridization was used to examine Epstein-Barr virus (EBV) infection, VEGF, and bFGF.
  
  
  RESULTS
  The positive rates of CD20, CD43/CD45RO, CD3, CD56, TIA-1, and CD44 were 0%, 88.2%, 70.6%, 88.2%, 100%, and 41.2%. Fifteen cases (88.2%) were positive in EBER1 (EBV infection). VEGF was expressed in 11 cases (64.7%). VEGF expression was negative in 2 out of 4 cases with angioinvasion, and negative in 4 cases out of 7 cases who died of tumor. bFGF was weakly expressed in 3 cases (17.6%) and was not expressed in 2 out of 4 cases with angioinvasion and 6 out of 7 cases who died of tumor. CD44 expression was negative in all 3 cases with dysplasia, and in 4 out of the 7 cases who died of tumor.
  
  
  CONCLUSIONS
  CD44 can not predict the potentiality of NK/T cells lymphoma in invasion, and does not correlate with prognosis. The expression of VEGF is far more frequent than that of bFGF in NK/T cells lymphoma. The significance of VEGF and bFGF expression remains to be investigated.
authors.affiliation: Department of Pathology, The First Hospital, Peking University, Beijing 100034, China.
authors.forename: T
authors.initials: T
authors.lastname: Li
authors.forename: D
authors.initials: D
authors.lastname: Liu
authors.forename: F
authors.initials: F
authors.lastname: Zhang
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000096:biosynthesis*; D016228:Endothelial Growth Factors / Q000096:biosynthesis; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis*; D007150:Immunohistochemistry / Q000379:methods; D017403:In Situ Hybridization / Q000379:methods; D007694:Killer Cells, Natural / Q000378:metabolism* / Q000473:pathology; D008222:Lymphokines / Q000096:biosynthesis; D016399:Lymphoma, T-Cell / Q000378:metabolism*; D009669:Nose Neoplasms / Q000378:metabolism; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D043925:Angiogenesis Inducing Agents; D016228:Endothelial Growth Factors; D018960:Hyaluronan Receptors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2